BIO-FD&C Co (251120) Fair Value & Analysis
Healthcare · KR · Market cap 65.9B KRW
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 19 days ago
Share price −2.9% over the past month.
A solid business, screening 22% undervalued on our models.
What matters now
- Our model range runs from 7,696 KRW (bear) to 13,430 KRW (bull), base 10,116 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 73/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
54‑month range 7,090 KRW – 28,300 KRW · fair‑value band 7,696 KRW – 13,430 KRW · the 8,300 KRW price screens below the 10,116 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
BIO-FD&C Co (251120) currently trades at 8,300 KRW, while our model-based Fair Value estimate is 10,116 KRW, implying the stock looks roughly 21.9% undervalued today. The Quality Score stands at 73/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, BIO-FD&C Co generated revenue of 18.9B KRW at a net margin of 32.9%. Revenue declined 7.5% year over year. It earns a return on equity of 9.1%. Net debt stands at 251M KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 7,696 KRW (bear case) to 13,430 KRW (bull case); at 8,300 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 64% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 22%, 251120 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (15,901 KRW) versus Asset-Based (5,483 KRW). Highest evidence: Growth DCF (80).
Notify me when 251120 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 21
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, natural extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, acne, skin irritation, wound healing, scalp improvement, skin moisturizing, fine dust, hair loss improvement, pores, lifting, whitening, …
Full company description
BIO-FD&C Co.,Ltd. develops active ingredients for anti-aging cosmetics in South Korea. It offers plant cell, peptide, natural extract, and biomolecule products for wrinkle improvement/skin regeneration, skin brightening, acne, skin irritation, wound healing, scalp improvement, skin moisturizing, fine dust, hair loss improvement, pores, lifting, whitening, skin texture, anti-inflammation/skin soothing, and anti-oxidation. The company was founded in 2005 and is headquartered in Incheon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BIO-FD&C Co reported revenue of 19.2B KRW in FY2025 versus 12.0B KRW in FY2021, a compound +12.5%/yr. Reported net income was 6.7B KRW in FY2025, compounding +23.1%/yr from FY2021.
Watch 251120: get an alert when its fair value changes →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare BIO-FD&C Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BIO-FD&C Co (251120) overvalued or undervalued?
What is the fair value of 251120?
What is the quality score of 251120?
What is the revenue of BIO-FD&C Co (251120)?
What is the net profit margin of 251120?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BIO-FD&C Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.